Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

Summary

The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.

Timeline

Start

2013-05

Primary completion

2016-01

Completion

2016-01

Outcome

Missed primary endpoint

Stopped: “Study sponsor was acquired by another company.”

registry analysis (superiority test); GLYX-13 vs Placebo; p = .10; Mean Difference (Net) .05; t-test, 2 sided NCT01844726 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rapastinel	Other / unclassified	5 mg/kg	Intravenous

Indications